Eton Pharma awarded second patent for ET-400; PDUFA target Feb 28, 2025

Eton Pharmaceuticals, Inc.

USPTO granted U.S. Patent No. 12,133,914 for ET-400 (liquid hydrocortisone), expiring 2043.
Second patent for ET-400; first patent (US 11,904,046) obtained in February 2024.
Additional U.S. patent application for ET-400 remains under review.
FDA NDA accepted with PDUFA target action date of February 28, 2025.
If approved, ET-400 would be the only FDA-approved liquid hydrocortisone formulation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.